None, D. S. S. & None, D. S. J. (2024). A Comparative Study of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyposis. Journal of Contemporary Clinical Practice, 10(1), 604-614.
MLA
None, Dr. Sameer Samuel and Dr. Shailesh Jain . "A Comparative Study of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyposis." Journal of Contemporary Clinical Practice 10.1 (2024): 604-614.
Chicago
None, Dr. Sameer Samuel and Dr. Shailesh Jain . "A Comparative Study of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyposis." Journal of Contemporary Clinical Practice 10, no. 1 (2024): 604-614.
Harvard
None, D. S. S. and None, D. S. J. (2024) 'A Comparative Study of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyposis' Journal of Contemporary Clinical Practice 10(1), pp. 604-614.
Vancouver
Dr. Sameer Samuel DSS, Dr. Shailesh Jain DSJ. A Comparative Study of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyposis. Journal of Contemporary Clinical Practice. 2024 Jan;10(1):604-614.
Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a persistent type 2-skewed inflammatory disease of the nose and paranasal sinuses that impairs quality of life, olfaction and sleep. Current guidelines advocate maximal medical therapy first, with endoscopic sinus surgery reserved for patients with inadequate control, but the relative benefit of the two approaches in routine Indian practice remains debated.Aim and objectives: To compare the clinical, endoscopic and radiological outcomes, quality-of-life gain, recurrence and complications of medical management versus functional endoscopic sinus surgery (FESS) with standard postoperative medical therapy in CRSwNP.Materials and methods: This prospective, randomised, comparative study was conducted in the Department of Otorhinolaryngology of a tertiary care teaching hospital from June 2022 to December 2023. One hundred adults with bilateral CRSwNP were allocated equally to Group A (medical therapy, n = 50) or Group B (FESS plus postoperative medical therapy, n = 50). Outcomes were the 22-item Sinonasal Outcome Test (SNOT-22), visual analogue scale (VAS) for symptoms and smell, Lund-Kennedy endoscopic score, endoscopic nasal polyp score and Lund-Mackay CT score at baseline, 3 months and 6 months. Data were analysed using t-tests and chi-square tests (p < 0.05).Results: Both groups were comparable at baseline. Mean SNOT-22 fell from 58.4 to 36.1 in Group A and from 60.2 to 18.4 in Group B at 6 months (between-group p < 0.001). Surgery produced greater improvement in endoscopic polyp score, CT score and smell VAS. Clinically meaningful SNOT-22 improvement occurred in 76% of Group A and 94% of Group B (p = 0.012), while polyp recurrence was 24% versus 8% (p = 0.029). Seven medically treated patients (14%) required rescue surgery. Complications in both groups were minor.Conclusion: Medical therapy is effective and safe as first-line treatment, but FESS with continued topical steroids gives superior and more durable symptomatic, endoscopic and olfactory outcomes in CRSwNP. A stepwise approach, with early surgery for patients with extensive disease or inadequate response, is appropriate
Keywords
Chronic rhinosinusitis
Nasal polyposis
Functional endoscopic sinus surgery
Intranasal corticosteroids
SNOT-22
Lund-Mackay score
INTRODUCTION
Chronic rhinosinusitis (CRS) is defined as inflammation of the nose and paranasal sinuses lasting twelve weeks or longer and characterised by two or more symptoms, one of which must be nasal blockage or nasal discharge, with or without facial pain or pressure and reduction or loss of smell, supported by endoscopic or CT evidence of mucosal disease [1,2]. It is conventionally divided into CRS without nasal polyps and CRS with nasal polyps (CRSwNP), the latter being recognised by the presence of bilateral, oedematous, grape-like polypoidal tissue in the middle meatus [2,3]. In a large European population survey the overall prevalence of CRS was 10.9%, and nasal polyps are thought to affect roughly 2 to 4% of adults [4,5].
CRSwNP is more than a local mucosal disorder. In Western populations it is typically associated with a type 2 inflammatory endotype characterised by eosinophilia, raised interleukin-5 and local immunoglobulin E production, and it frequently coexists with asthma, aspirin-exacerbated respiratory disease and allergic rhinitis [6,7]. Patients suffer nasal obstruction, anosmia, mucous discharge, sleep disturbance and impaired productivity, and the disease imposes a considerable economic burden through repeated consultations, drug use and surgery [8]. Indian otolaryngology texts describe nasal polyposis as one of the commonest causes of chronic nasal obstruction seen in outpatient practice, and a significant proportion of Indian patients present late with extensive disease [9,10]. In the Indian subcontinent the picture is further complicated by a notable burden of allergic and non-invasive fungal rhinosinusitis, which has been well documented by workers from northern India and must be distinguished from ordinary CRSwNP because its management differs [11,12].
Medical therapy forms the foundation of management. Intranasal corticosteroids (INCS) and saline irrigation are first-line, and a short course of oral corticosteroids produces rapid reduction in polyp size and symptoms [13,14,15]. Systemic steroids, however, carry recognised short-term adverse effects, and their benefit is frequently lost within weeks to months of stopping treatment [16,17]. Topical therapy delivered with sufficient volume and correct technique remains central to long-term control [18].
Surgery, in the form of functional endoscopic sinus surgery (FESS), follows the principles introduced by Messerklinger and popularised by Kennedy and Stammberger, namely the restoration of ventilation and drainage of the osteomeatal complex with preservation of normal mucosa [19,20]. Current consensus documents and clinical practice guidelines recommend that surgery be offered to adults with CRSwNP who remain symptomatic after an adequate trial of appropriate medical therapy [21,22,23]. Surgery removes the polyp burden, widens access for topical agents and may improve smell, but it does not cure the underlying disease, and polyps recur in a substantial proportion of patients [24,25,26].
Prospective studies comparing the two strategies have generally shown meaningful improvement with both, but the magnitude, durability and cost-effectiveness differ between settings, and most of the high-quality evidence is derived from Western cohorts [27,28,29]. Newer biologic agents have shown impressive results in severe uncontrolled disease, yet cost and availability restrict their use in most Indian hospitals [30,31]. Local data on how medical and surgical management compare in patients attending Indian tertiary centres are therefore valuable. The present study was undertaken to compare these two approaches in patients with CRSwNP using validated symptom, endoscopic and radiological measures.
1.1 Aim and objectives
Aim: To compare the outcomes of medical and surgical management in patients with chronic rhinosinusitis with nasal polyposis.
Objectives: (1) To compare symptom and quality-of-life improvement using SNOT-22 and VAS between the two groups; (2) to compare endoscopic and CT scores before and after treatment; (3) to compare olfactory outcome, recurrence, need for rescue surgery and patient satisfaction; and (4) to document the complications of each treatment modality..
MATERIALS AND METHODS
2.1 Study design and setting
This was a hospital-based, prospective, randomised, open-label, comparative study conducted in the Department of Otorhinolaryngology of a tertiary care teaching hospital. The study period was 18 months, with patient recruitment from June 2022 to December 2023. Institutional Ethics Committee approval was obtained before commencement, and written informed consent was taken from every participant.
2.2 Study population and sample size
Of 112 adults assessed for eligibility, 12 were excluded and 100 were enrolled. The sample size was calculated using the formula for comparison of two means, assuming a standard deviation of 13 points for SNOT-22, a minimum difference of 8 points between groups (close to the minimal clinically important difference), 5% significance level and 80% power. This gave about 42 patients per group, which was increased to 50 per group to allow for loss to follow-up. Patients were allocated 1:1 to Group A or Group B using a computer-generated random number table with sealed opaque envelopes.
2.3 Inclusion criteria
Patients aged 18 years or above with bilateral CRSwNP diagnosed according to the EPOS criteria (symptoms for at least 12 weeks, endoscopic evidence of bilateral polyps arising from the middle meatus, and CT changes in the paranasal sinuses) [2], who consented to participate and to attend follow-up, were included.
2.4 Exclusion criteria
Patients with unilateral polyps, antrochoanal polyp, suspected sinonasal neoplasm, allergic fungal or invasive fungal rhinosinusitis [11], cystic fibrosis, primary ciliary dyskinesia, immunodeficiency, previous sinonasal surgery, pregnancy, uncontrolled diabetes or hypertension, or any contraindication to systemic corticosteroids or general anaesthesia were excluded.
2.5 Baseline evaluation
A detailed history, clinical examination and diagnostic nasal endoscopy (0 degree and 30 degree rigid endoscopes) were performed in all patients. Non-contrast CT of the nose and paranasal sinuses (axial and coronal, 1 mm cuts) was obtained and graded using the Lund-Mackay system (0 to 24) [32]. Endoscopic findings were scored with the Lund-Kennedy system (0 to 20) [33], and polyp size was graded using the endoscopic nasal polyp score (0 to 4 per side, total 0 to 8). Symptom burden was measured with the validated 22-item Sinonasal Outcome Test (SNOT-22; range 0 to 110, higher scores indicating worse quality of life) [34]. Overall symptom severity and sense of smell were recorded on 10-cm visual analogue scales (VAS). Routine blood counts including absolute eosinophil count, blood sugar and, where indicated, allergy testing were done.
2.6 Interventions
Group A (medical therapy): Patients received oral prednisolone 0.5 mg/kg/day for 7 days, tapered over the following 7 days; mometasone furoate nasal spray (2 sprays per nostril twice daily for 4 weeks, then once daily) for 12 weeks; daily isotonic saline irrigation for 12 weeks; a second-generation oral antihistamine for patients with allergic rhinitis; and a 14-day course of amoxicillin-clavulanate if purulent discharge was present. Contraindications to steroids were screened before every prescription.
Group B (surgical therapy): Patients received oral prednisolone 0.5 mg/kg/day for 5 days before surgery to reduce bleeding and polyp volume. FESS (uncinectomy, anterior and, where required, posterior ethmoidectomy, middle meatal antrostomy and frontal or sphenoid sinusotomy according to CT extent of disease) was performed by the same surgical team under general anaesthesia using the Messerklinger technique [20]. Postoperatively, patients received the same INCS and saline irrigation regimen as Group A for 12 weeks, with regular endoscopic toilet at 1, 2 and 4 weeks. Patients in both groups who failed to respond were offered rescue treatment as described below.
2.7 Outcome measures and follow-up
Patients were reviewed at 1 month, 3 months and 6 months. SNOT-22, VAS, Lund-Kennedy score and nasal polyp score were recorded at baseline, 3 months and 6 months, and the Lund-Mackay CT score was repeated at 6 months in all patients who consented to repeat low-dose imaging. A reduction in SNOT-22 of at least 9 points was taken as clinically meaningful improvement (responder). Polyp recurrence was defined as endoscopic return of polyps with symptoms requiring additional systemic steroid therapy. Rescue surgery in Group A and revision surgery in Group B were recorded. Patient satisfaction was graded on a 5-point Likert scale and ratings of satisfied or very satisfied were considered favourable. Medication-related and operative complications were documented. In the intention-to-treat analysis, the last observed values before rescue surgery were carried forward for Group A patients.
2.8 Statistical analysis
Data were entered in Microsoft Excel and analysed with SPSS version 26.0. Continuous variables were expressed as mean ± standard deviation and compared using the independent samples t-test between groups and the paired t-test within groups. Categorical variables were expressed as number (percentage) and compared with the chi-square or Fisher's exact test. A p-value below 0.05 was considered statistically significant.
RESULTS
A total of 100 patients (50 in each group) were enrolled, and all completed the 6-month follow-up. The two groups were comparable with respect to age, sex, duration of symptoms, comorbidities and all baseline severity measures.
3.1 Demographic profile
Patient age ranged from 18 to 72 years with an overall mean of 39.4 ± 11.0 years (Group A 38.6 ± 11.2 years; Group B 40.1 ± 10.8 years; p = 0.50). The commonest age group was 31 to 40 years (29%), followed by 41 to 50 years (27%) (Table 1). There were 60 males and 40 females (male to female ratio 1.5:1), and the sex distribution did not differ significantly between the groups.
Table 1: Age and sex distribution of study participants (N = 100)
Variable Group A (n = 50) Group B (n = 50) Total (N = 100) p-value
Age group (years) 0.97
18 - 30 12 (24%) 10 (20%) 22 (22%)
31 - 40 15 (30%) 14 (28%) 29 (29%)
41 - 50 13 (26%) 14 (28%) 27 (27%)
51 - 60 7 (14%) 9 (18%) 16 (16%)
> 60 3 (6%) 3 (6%) 6 (6%)
Sex 0.68
Male 29 (58%) 31 (62%) 60 (60%)
Female 21 (42%) 19 (38%) 40 (40%)
Chi-square test; p > 0.05 indicates no significant difference between groups.
3.2 Clinical profile and comorbidities
The mean duration of symptoms was 3.8 ± 2.1 years in Group A and 4.1 ± 2.3 years in Group B (p = 0.50). Nasal obstruction was present in all patients, followed by nasal discharge or postnasal drip (86%), hyposmia or anosmia (78%), headache or facial pressure (62%) and sneezing (54%) (Table 2). Deviated nasal septum was the commonest associated anatomical finding (41%), while allergic rhinitis (34%) and bronchial asthma (21%) were the commonest systemic associations (Table 3). Aspirin sensitivity was noted in four patients (4%).
Table 2: Presenting symptoms (N = 100)
Symptom Group A (n = 50) Group B (n = 50) Total (N = 100) p-value
Nasal obstruction 50 (100%) 50 (100%) 100 (100%) 1.00
Nasal discharge / postnasal drip 43 (86%) 43 (86%) 86 (86%) 1.00
Hyposmia / anosmia 38 (76%) 40 (80%) 78 (78%) 0.63
Headache / facial pressure 30 (60%) 32 (64%) 62 (62%) 0.68
Sneezing 28 (56%) 26 (52%) 54 (54%) 0.69
Chi-square test; multiple symptoms per patient.
Table 3: Associated conditions and baseline characteristics (N = 100)
Variable Group A (n = 50) Group B (n = 50) Total (N = 100) p-value
Deviated nasal septum 19 (38%) 22 (44%) 41 (41%) 0.54
Allergic rhinitis 16 (32%) 18 (36%) 34 (34%) 0.67
Bronchial asthma 10 (20%) 11 (22%) 21 (21%) 0.80
Tobacco use (smoked or smokeless) 10 (20%) 12 (24%) 22 (22%) 0.63
Aspirin sensitivity 2 (4%) 2 (4%) 4 (4%) 1.00
Duration of symptoms (years), mean ± SD 3.8 ± 2.1 4.1 ± 2.3 3.9 ± 2.2 0.50
Chi-square / Fisher's exact test for categorical data; independent t-test for duration.
3.3 Quality of life (SNOT-22)
Baseline SNOT-22 scores were similar (58.4 ± 12.6 versus 60.2 ± 13.1; p = 0.49). At 3 months the mean score had fallen to 34.2 ± 10.4 in Group A and 22.6 ± 9.2 in Group B (p < 0.001). Between 3 and 6 months the benefit of medical therapy partly waned (36.1 ± 11.6 at 6 months), whereas Group B continued to improve (18.4 ± 8.6), so that the mean reduction from baseline was 22.3 points in Group A and 41.8 points in Group B (Table 4, Figure 1). Improvement from baseline was significant within each group at both time points (paired t-test, p < 0.001).
Table 4: Comparison of SNOT-22 scores between groups
Time point Group A (mean ± SD) Group B (mean ± SD) t-value p-value
Baseline 58.4 ± 12.6 60.2 ± 13.1 0.70 0.49
3 months 34.2 ± 10.4 22.6 ± 9.2 5.90 < 0.001
6 months 36.1 ± 11.6 18.4 ± 8.6 8.67 < 0.001
Change at 6 months 22.3 ± 12.0 41.8 ± 12.3 7.99 < 0.001
Independent samples t-test; SNOT-22 range 0 - 110.
3.4 Symptom severity and olfaction (VAS)
The overall symptom VAS decreased in both groups, but the reduction was greater after surgery at 3 and 6 months. Smell improved in both groups at 3 months; however, at 6 months the mean olfactory VAS had regressed in Group A (5.4 to 4.8) while it remained high in Group B (6.5), a difference that was statistically significant (Table 5).
Table 5: Symptom VAS (0 - 10, lower is better) and olfaction VAS (0 - 10, higher is better)
Parameter / time Group A (mean ± SD) Group B (mean ± SD) t-value p-value
Symptom VAS - baseline 7.4 ± 1.2 7.5 ± 1.1 0.43 0.67
Symptom VAS - 3 months 4.1 ± 1.5 2.8 ± 1.3 4.63 < 0.001
Symptom VAS - 6 months 4.4 ± 1.6 2.5 ± 1.2 6.71 < 0.001
Smell VAS - baseline 3.2 ± 1.8 3.0 ± 1.9 0.54 0.59
Smell VAS - 3 months 5.4 ± 2.0 6.8 ± 1.9 3.59 < 0.001
Smell VAS - 6 months 4.8 ± 2.1 6.5 ± 2.0 4.16 < 0.001
Independent samples t-test.
3.5 Endoscopic and radiological outcomes
Endoscopic findings were significantly better in the surgical group at both follow-up visits. The mean nasal polyp score at 6 months was 3.6 ± 1.5 in Group A against 1.6 ± 1.1 in Group B (p < 0.001), and the Lund-Kennedy score showed a similar trend. The Lund-Mackay CT score at 6 months was 11.6 ± 3.9 in Group A and 6.2 ± 3.1 in Group B (p < 0.001) (Table 6). In Group A the polyp score rose between 3 and 6 months after discontinuation of oral steroids, indicating partial relapse.
Table 6: Endoscopic and CT scores
Parameter / time Group A (mean ± SD) Group B (mean ± SD) t-value p-value
Lund-Kennedy score - baseline 9.6 ± 2.1 9.9 ± 2.0 0.73 0.47
Lund-Kennedy score - 3 months 6.1 ± 2.0 3.4 ± 1.8 7.11 < 0.001
Lund-Kennedy score - 6 months 6.6 ± 2.2 3.1 ± 1.7 8.91 < 0.001
Polyp score - baseline 5.2 ± 1.3 5.4 ± 1.2 0.80 0.42
Polyp score - 3 months 3.1 ± 1.4 1.3 ± 1.0 7.41 < 0.001
Polyp score - 6 months 3.6 ± 1.5 1.6 ± 1.1 7.60 < 0.001
Lund-Mackay CT - baseline 14.8 ± 3.6 15.3 ± 3.4 0.71 0.48
Lund-Mackay CT - 6 months 11.6 ± 3.9 6.2 ± 3.1 7.66 < 0.001
Independent samples t-test. Lund-Kennedy 0 - 20; polyp score 0 - 8; Lund-Mackay 0 - 24.
3.6 Treatment response, recurrence and satisfaction
Clinically meaningful improvement in SNOT-22 at 6 months was achieved by 38 patients (76%) in Group A and 47 patients (94%) in Group B (p = 0.012). Polyp recurrence occurred in 12 patients (24%) of Group A and 4 patients (8%) of Group B (p = 0.029). Seven patients (14%) in Group A required rescue surgery for inadequate control, compared with two (4%) needing revision surgery in Group B, a difference that did not reach significance (p = 0.16). Group A patients needed more additional courses of systemic steroids, and favourable satisfaction ratings were significantly higher after surgery (Table 7). The mean direct cost of treatment over 6 months was approximately INR 9,800 for Group A and INR 38,500 for Group B.
Table 7: Treatment outcomes at 6 months
Outcome Group A (n = 50) Group B (n = 50) Test value p-value
SNOT-22 responders (reduction >= 9) 38 (76%) 47 (94%) chi-sq 6.35 0.012
Polyp recurrence / relapse 12 (24%) 4 (8%) chi-sq 4.76 0.029
Rescue / revision surgery 7 (14%) 2 (4%) Fisher 0.16
Additional steroid courses, mean ± SD 0.9 ± 0.8 0.3 ± 0.5 t = 4.50 < 0.001
Satisfied / very satisfied 33 (66%) 44 (88%) chi-sq 6.83 0.009
Responder: SNOT-22 reduction of at least 9 points from baseline.
3.7 Complications and adverse effects
No major complication such as cerebrospinal fluid leak, orbital injury or meningitis occurred in any patient. Minor adverse events in Group A were largely steroid-related, including dyspepsia (14%), insomnia or mood change (8%) and transient hyperglycaemia (4%), together with nasal dryness (18%) and minor epistaxis (12%). In Group B, minor bleeding (16%), crusting (22%) and synechiae (10%) were the commonest events, and all synechiae were released in the outpatient setting (Table 8).
Table 8: Complications and adverse effects
Event Group A (n = 50) Group B (n = 50)
Minor epistaxis / intra- or postoperative bleeding 6 (12%) 8 (16%)
Nasal dryness / crusting 9 (18%) 11 (22%)
Steroid-related dyspepsia 7 (14%) 3 (6%)
Insomnia / mood change 4 (8%) 1 (2%)
Transient hyperglycaemia 2 (4%) 0
Synechiae 0 5 (10%)
Ostial stenosis 0 2 (4%)
Periorbital ecchymosis 0 2 (4%)
Major complication (CSF leak, orbital injury, meningitis) 0 0
All events were minor and managed conservatively. Percentages are of the group total.
3.8 Exploratory subgroup observations
In an exploratory analysis the 6-month SNOT-22 reduction was examined according to coexisting asthma and baseline blood eosinophilia (absolute eosinophil count of 300 cells/microlitre or more, present in 46 patients). Patients with asthma tended to gain less than those without asthma in both groups, and in the medical group those with eosinophilia derived more benefit than those without, whereas in the surgical group the gain was similar irrespective of eosinophil count (Table 9). Because these subgroups were small, no formal comparison was made and the findings should be regarded as hypothesis-generating.
Table 9: Exploratory subgroup analysis - mean reduction in SNOT-22 at 6 months
Subgroup Group A: n Group A: mean ± SD Group B: n Group B: mean ± SD
Coexisting asthma 10 17.8 ± 11.4 11 36.9 ± 12.9
No asthma 40 23.5 ± 11.8 39 43.2 ± 11.9
Eosinophils >= 300 cells/microlitre 22 25.4 ± 11.6 24 42.5 ± 12.1
Eosinophils < 300 cells/microlitre 28 19.9 ± 12.0 26 41.2 ± 12.6
Descriptive data; subgroups not powered for comparison
DISCUSSION
The management of CRSwNP is based on a stepwise principle in which medical therapy is optimised first and surgery is considered when control is inadequate. This study compared both strategies prospectively in 100 patients and found that, although medical therapy produced a substantial initial improvement, surgery followed by continued topical therapy gave larger and better sustained gains in quality of life, endoscopic appearance, radiological disease and smell, with an acceptable complication rate.
The demographic profile of our cohort, with a mean age near 40 years and a male predominance, is in keeping with the classical description of nasal polyposis as a disease of early to middle adult life affecting men more often than women. Nasal obstruction was universal and smell loss was reported by about four of every five patients, which agrees with the symptom pattern described in European and North American cohorts and in the national comparative audit of surgery for nasal polyposis in the United Kingdom [35]. The high prevalence of deviated septum in our series (41%) is probably explained by referral of obstructed patients to a tertiary centre, whereas the 21% frequency of asthma underlines the need to screen every patient for lower airway disease.
Both groups showed a significant fall in SNOT-22 from baseline. Medical therapy lowered the mean score by 22.3 points, which is well above the
minimal clinically important difference of the instrument, but the gain was smaller than the 41.8-point reduction achieved by surgery [34]. The pattern of an early benefit with partial loss of effect after the end of oral steroid therapy in Group A is consistent with randomised evidence that short courses of systemic corticosteroids rapidly improve symptoms and polyp size, but that this effect is transient unless maintained by topical therapy. Conversely, the continued improvement in Group B between 3 and 6 months mirrors the mucosal healing after endoscopic surgery and the improved delivery of topical steroid to the sinus cavities.
Our findings broadly agree with earlier comparative work. Ragab and colleagues, in a randomised trial, observed meaningful improvement with both treatments and concluded that surgery should be reserved for patients who do not respond to adequate medical therapy. Alobid et al. similarly found that quality of life improved with both medical and surgical treatment of nasal polyposis. The multi-institutional prospective cohorts of Smith and co-workers showed that patients who elected surgery after failure of medical therapy gained significantly more benefit than those who continued with medical treatment, and that the improvement persisted at one year [36]. The United Kingdom national audit documented a large and sustained fall in SNOT-22 after surgery in patients with polyposis, with only a minority requiring revision [35]. Our results, obtained in an Indian tertiary centre, are therefore in line with international experience, even though our groups were randomised from the outset rather than assigned after medical failure.
Endoscopic polyp score and Lund-Kennedy score improved in both groups, but surgery achieved a markedly lower residual disease burden, and the CT score at 6 months was nearly halved in Group B relative to Group A. Complete removal of the polyp mass and ethmoid cells, together with opening of the sinus ostia, would be expected to reduce the radiological score, whereas medical therapy shrinks polyps and mucosal oedema without removing the underlying bony and anatomical contributors.
Olfaction is the symptom most troublesome to many patients with polyposis and often the most difficult to restore. Smell improved at 3 months in both groups, but only the surgical group retained a clear benefit at 6 months. DeConde et al. likewise reported that both medical and surgical approaches improve olfaction in CRS, with greater gains in patients undergoing surgery [37]. The regression of smell in our medically treated patients after steroid withdrawal reflects the recurrence of obstructive polyps and mucosal oedema in the olfactory cleft, and suggests that patients for whom smell is the dominant complaint may be better served by earlier surgical intervention combined with long-term topical steroids.
Polyp recurrence was three times more frequent in the medical group (24% versus 8%). The recurrence rate in the surgical group at 6 months is lower than the rates reported in long-term series, because polyps recur with time in CRSwNP, particularly in patients with asthma, eosinophilic disease and extensive baseline involvement. Our short follow-up therefore underestimates the long-term recurrence burden of both groups. Seven patients (14%) in the medical arm eventually required rescue surgery, which supports the established concept that a subset of patients will not achieve control with drugs alone. Satisfaction was significantly higher in the surgical group, probably reflecting the greater improvement in nasal airway and smell.
Complications were minor in both groups. The adverse events in Group A were typical of systemic and topical corticosteroids and underline the need to limit oral steroid courses and to monitor glycaemic status, especially in diabetic patients. In the surgical group, bleeding, crusting and synechiae were the commonest problems and were managed with endoscopic toilet and outpatient adhesiolysis. There was no major complication, which is consistent with the safety of FESS when performed by experienced surgeons with CT-guided planning and a careful understanding of the skull base and orbit.
In India, patients frequently present late with extensive disease and may interrupt long-term medical treatment because of cost, travel and limited access to follow-up. In this setting the higher upfront cost of surgery (about four times that of medical therapy in our sample) has to be weighed against the repeated courses of drugs, additional steroid exposure and lost working days seen with medical management alone. Biologic agents such as dupilumab and omalizumab have shown clear efficacy in severe uncontrolled CRSwNP, but their cost puts them out of reach of most patients and they remain a later-line option. A dedicated workup for fungal disease remains essential in Indian practice, since allergic fungal rhinosinusitis behaves differently and needs surgery with adjunctive steroids rather than medical therapy alone. These practical considerations favour a pragmatic algorithm in which every patient receives an adequate trial of INCS, saline irrigation and a short course of oral steroid, and in which surgery is offered early to those with extensive disease on CT, prominent smell loss, associated anatomical obstruction, or an inadequate response.
Our exploratory observations suggest that the benefit of medical therapy is not uniform. Patients with higher blood eosinophil counts improved more with corticosteroids, which is biologically plausible because steroids suppress eosinophilic type 2 inflammation, whereas patients with coexisting asthma gained less in both arms and are known to experience earlier and more frequent recurrence. The observation that surgical gain was similar irrespective of eosinophil count is consistent with the mechanical advantages of surgery, namely debulking, creation of access and improved topical delivery, which do not depend on the inflammatory endotype. Although tissue-based endotyping was not available to us, simple parameters such as asthma status, blood eosinophil count and CT extent may help to identify patients who are unlikely to be controlled by medical therapy alone and who should be counselled early about surgery.
Surgery should not be regarded as an alternative to medical therapy but as a means of making medical therapy more effective. In our study every operated patient continued INCS and saline irrigation, and attended scheduled endoscopic cleaning, which may partly account for the good outcome and low synechiae rate. Evidence indicates that topical steroids reduce polyp recurrence after surgery, and that delivery to the sinus cavities is far better after the sinuses have been opened. Conversely, disease control in medically treated patients depends heavily on adherence to daily sprays and irrigation, which is difficult to maintain over months. Counselling about technique, the expected time course of improvement and the likelihood of recurrence should therefore be an integral part of both pathways, and may be as important as the choice between them.
Strengths and future directions
The strengths of the present study include its prospective randomised design, comparable baseline groups, use of validated patient-reported, endoscopic and radiological outcome measures, standardised treatment protocols and complete follow-up of all participants. Future research should include longer follow-up of at least 2 to 5 years, formal cost-effectiveness analysis in the Indian context, correlation with tissue eosinophilia and other biomarkers, and comparison of surgery with newer biologic therapies as these become more accessible. Until such data are available, the present findings support an individualised stepwise strategy in which the intensity and timing of surgery are guided by disease extent, symptom profile, comorbidities and patient preference.
4.9 Limitations
The study has several limitations. It was a single-centre study with a modest sample size and a short follow-up of 6 months, which is insufficient to capture long-term recurrence. Blinding was not possible because of the nature of the interventions. Inflammatory endotyping by tissue eosinophilia was not performed, and cost analysis was limited to direct costs. Larger multicentre studies with longer follow-up are required to confirm these observations.
CONCLUSION
In patients with chronic rhinosinusitis with nasal polyposis, both medical therapy and functional endoscopic sinus surgery produced significant improvement in symptoms, quality of life, endoscopic appearance and CT scores. Medical therapy is safe, inexpensive and appropriate as first-line treatment, but its benefits are partly lost after steroid withdrawal and a significant minority eventually need surgery. FESS followed by continued topical steroid therapy achieved greater and more durable improvement in SNOT-22, polyp score, radiological score and olfaction, with higher patient satisfaction, lower recurrence and only minor complications. A stepwise approach is recommended, with early surgical intervention in patients with extensive disease, marked smell loss or inadequate response to an adequate trial of medical treatment.
REFERENCES
1. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol. 2004;114(6 Suppl):155-212.
2. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.
3. Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg. 2003;129(3 Suppl):S1-S32.
4. Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study. Allergy. 2011;66(9):1216-1223.
5. Hopkins C. Chronic rhinosinusitis with nasal polyps. N Engl J Med. 2019;381(1):55-63.
6. Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4(4):565-572.
7. Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017;12:331-357.
8. Bhattacharyya N. Incremental healthcare utilization and expenditures for chronic rhinosinusitis in the United States. Ann Otol Rhinol Laryngol. 2011;120(7):423-427.
9. Dhingra PL, Dhingra S. Diseases of Ear, Nose and Throat & Head and Neck Surgery. 7th ed. New Delhi: Elsevier; 2018.
10. Rajguru R. Nasal polyposis: current trends. Indian J Otolaryngol Head Neck Surg. 2014;66(Suppl 1):16-21.
11. Chakrabarti A, Denning DW, Ferguson BJ, et al. Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope. 2009;119(9):1809-1818.
12. Panda NK, Sharma SC, Chakrabarti A, Mann SB. Paranasal sinus mycoses in north India. Mycoses. 1998;41(7-8):281-286.
13. Chong LY, Head K, Hopkins C, et al. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011993.
14. Kalish L, Snidvongs K, Sivasubramaniam R, Cope D, Harvey RJ. Topical steroids for nasal polyps. Cochrane Database Syst Rev. 2012;12:CD006549.
15. Hissaria P, Smith W, Wormald PJ, et al. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol. 2006;118(1):128-133.
16. Patiar S, Reece P. Oral steroids for nasal polyps. Cochrane Database Syst Rev. 2007;(1):CD005232.
17. Poetker DM, Jakubowski LA, Lal D, Hwang PH, Wright ED, Smith TL. Oral corticosteroids in the management of adult chronic rhinosinusitis with and without nasal polyps: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2013;3(2):104-120.
18. Harvey RJ, Psaltis A, Schlosser RJ, Witterick IJ. Current concepts in topical therapy for chronic sinonasal disease. J Otolaryngol Head Neck Surg. 2010;39(3):217-231.
19. Kennedy DW. Functional endoscopic sinus surgery. Technique. Arch Otolaryngol. 1985;111(9):643-649.
20. Stammberger H, Posawetz W. Functional endoscopic sinus surgery. Concept, indications and results of the Messerklinger technique. Eur Arch Otorhinolaryngol. 1990;247(2):63-76.
21. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1-S39.
22. Orlandi RR, Kingdom TT, Hwang PH, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22-S209.
23. Rudmik L, Soler ZM, Hopkins C, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology. 2016;54(2):117-128.
24. Dalziel K, Stein K, Round A, Garside R, Royle P. Systematic review of endoscopic sinus surgery for nasal polyps. Health Technol Assess. 2003;7(17):iii,1-159.
25. Wynn R, Har-El G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2004;114(5):811-813.
26. Calus L, Van Bruaene N, Bosteels C, et al. Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with and without nasal polyposis. Clin Transl Allergy. 2019;9:30.
27. Ragab SM, Lund VJ, Scadding G. Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomised, controlled trial. Laryngoscope. 2004;114(5):923-930.
28. Alobid I, Benitez P, Bernal-Sprekelsen M, et al. Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy. 2005;60(4):452-458.
29. Smith TL, Kern R, Palmer JN, et al. Medical therapy vs surgery for chronic rhinosinusitis: a prospective, multi-institutional study. Int Forum Allergy Rhinol. 2011;1(6):235-241.
30. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650.
31. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-116.e1.
32. Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology. 1993;31(4):183-184.
33. Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg. 1997;117(3 Pt 2):S35-S40.
34. Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5):447-454.
35. Hopkins C, Browne JP, Slack R, Lund V, Brown P. The national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Clin Otolaryngol. 2006;31(5):390-398.
36. Smith TL, Kern RC, Palmer JN, et al. Medical therapy vs surgery for chronic rhinosinusitis: a prospective, multi-institutional study with 1-year follow-up. Int Forum Allergy Rhinol. 2013;3(1):4-9.
37. DeConde AS, Mace JC, Alt JA, Schlosser RJ, Smith TL, Soler ZM. Comparative effectiveness of medical and surgical therapy on olfaction in chronic rhinosinusitis: a prospective, multi-institutional study. Int Forum Allergy Rhinol. 2014;4(9):725-733.
Recommended Articles
Original Article
A Study Of The Clinicopathological Profile Of Oral Cavity Malignancies In A Tertiary Care Centre
Adenoidectomy and Endoscopic Myringotomy with and without ventilation tube insertion for Treatment of Otitis Media with Effusion in 6-12 years old Children.